Cancer research stories

Oct 23, 2026

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 20262 sources

Top claims

▪Tango Therapeutics previously reported June 2026 data from 12 patients in its vopimetostat-Rasonque trial showing a 92% response rate and a six-month progression-free survival rate of 90%
▪An updated Phase 1/2 trial of Tango Therapeutics' vopimetostat combined with Revolution Medicines' Rasonque (daraxonrasib) showed an 82% objective response rate in 22 evaluable patients with advanced pancreatic cancer
▪The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to Revolution Medicines' daraxonrasib for first-line pancreatic cancer in September 2026

Subtopics

Cancer & Oncology1 Cancer treatment1 Cancer treatment breakthroughs1 Clinical trials1 Drug development1 Oncology1 Targeted cancer therapy1

Related timelines